Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Coil reactors - Homogeneous Reactions

Product Description

Cylinders.gifUniqsis offers interchangeable coil reactors in a range of sizes (2 ml to 20 ml) and materials (perfluoropolymer, stainless steel, Hastelloy?). These are fabricated from 1 mm internal diameter tubing wound onto an aluminium mandrel.

Smaller volume coils can be utilised for optimisation minimising material usage. Larger coils meet the requirements for scale up or longer residence times. Additional coil reactor volumes can be obtained by winding with tubing of diffferent internal dimensions.

The coil reactors are mounted on a purpose-built heated reactor module and can be changed in seconds. Reaction temperatures can be accurately controlled up to 260 °C.

Coil reactors can be re-wound if necessary (for example if they they are inadvertently blocked and can't be cleared). Note: When using perfluoropolymer tubing, this should be replaced periodically as a matter of course since it becomes 'fatigued' after repeated heat and pressure cycling. 

Benefits

  • Flexible - A range of materials and sizes are available for maximum chemical compatibility
  • Safety - FlowSyn limits temperature and pressure limit based on the coil material
  • High Performance - Coil design ensures excellent heat transfer
  • Visibility - Reactions performed in perfluoropolymer tubing are clearly visible through the glass coil cover
Features
  • Sizes from 2 ml to 20 ml available
  • LT Teflon for temps up to 100 °C
  • HT Teflon for temps up to 150 °C
  • Stainless steel or Hastelloy for temps up to 260 °C
Product Coil reactors - Homogeneous Reactions
Company Uniqsis
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Uniqsis
29 Station Road Shepreth Cambridgeshire SG8 6GB UK

Tel: +44 (0)845 864 7747

Email: info@uniqsis.com



Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!